Literature DB >> 11287454

Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.

S W Baxter, I G Campbell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11287454     DOI： 10.1093/jnci/93.7.557

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  8 in total

1.  ERBB2 genetic polymorphism and breast cancer risk in Chinese women: a population-based case-control study.

Authors:  Shimian Qu; Qiuyin Cai; Yu-Tang Gao; Wei Lu; Hui Cai; Yinghao Su; Shizhen Emily Wang; Xiao-Ou Shu; Wei Zheng
Journal:  Breast Cancer Res Treat       Date:  2007-08-09       Impact factor: 4.872

2.  HER2 Ile655Val polymorphism is negatively associated with breast cancer susceptibility.

Authors:  Felipe Campos de Almeida; Bruna Karina Banin Hirata; Carolina Batista Ariza; Roberta Losi Guembarovski; Karen Brajão de Oliveira; Karen Mayumi Suzuki; Alda Losi Guembarovski; Julie Massayo Maeda Oda; Glauco Akelinghton Freire Vitiello; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2018-02-08       Impact factor: 2.352

3.  HER2 Ile655Val and PTEN IVS4 polymorphisms in patients with breast cancer.

Authors:  Oguz Ozturk; Emel Canbay; Ozlem T Kahraman; M Fatih Seyhan; Fatih Aydogan; Varol Celik; Cihan Uras
Journal:  Mol Biol Rep       Date:  2012-10-21       Impact factor: 2.316

4.  HER2Ile655Val Single Nucleotide Polymorphism Associated with Early-Onset Breast Cancer Susceptibility: A Systematic Review and Meta-Analysis.

Authors:  Tung Nguyen Thanh; Bao Song Nguyen Tran; Ai Phuong Hoang Thi; Thang Tran Binh; Thong Ba Nguyen; Tam Le Minh; Quoc Huy Nguyen Vu; Thuan Dang Cong
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

5.  A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer.

Authors:  Stephanie E Nelson; Michael N Gould; John M Hampton; Amy Trentham-Dietz
Journal:  Breast Cancer Res       Date:  2005-03-11       Impact factor: 6.466

6.  c-erbB-2 is not a major factor in the development of colorectal cancer.

Authors:  J A McKay; J F Loane; V G Ross; M-M Ameyaw; G I Murray; J Cassidy; H L McLeod
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

7.  Common ERBB2 polymorphisms and risk of breast cancer in a white British population: a case-control study.

Authors:  Patrick R Benusiglio; Fabienne Lesueur; Craig Luccarini; Donald M Conroy; Mitul Shah; Douglas F Easton; Nick E Day; Alison M Dunning; Paul D Pharoah; Bruce Aj Ponder
Journal:  Breast Cancer Res       Date:  2005-01-12       Impact factor: 6.466

8.  Her2 Ile655Val polymorphism and its association with breast cancer risk: an updated meta-analysis of case-control studies.

Authors:  B Madhu Krishna; Sanjib Chaudhary; Aditya K Panda; Dipti Ranjan Mishra; Sandip K Mishra
Journal:  Sci Rep       Date:  2018-05-09       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.